Interview with Robert Coffin, inventor of T-VEC: the first oncolytic immunotherapy approved for the treatment of cancer

被引：48

作者：

Clarke, Ellen ^{[1
]}

Coffin, Robert ^{[2
]}

机构：

[1] Future Sci Grp, London, England

[2] Replimune Ltd, Oxford Sci Pk Magdalen Ctr, Robinson Ave, Oxford OX4 4GA, England

来源：

IMMUNOTHERAPY | 2016年 / 8卷 / 02期

关键词：

Imlygic; oncolytic immunotherapy; T-VEC;

D O I：

10.2217/imt.15.116

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Robert Coffin is co-founder and CEO of Replimune. Previously he was Founder and CTO of BioVex Inc, a spin out from his research group at University College London in 1999. He was the inventor of all BioVex products including OncoVEXGM-CSF (talimogene laherparepvec; T-VEC; Imlygic) and oversaw all research and clinical development including bringing T-VEC through to two pivotal Phase 3 studies in melanoma and head and neck cancer. BioVex was acquired by Amgen in 2011 where he was VP Global Development until 2013. T-VEC was approved by the FDA for use in advanced melanoma in October 2015, the first oncolytic therapy or gene therapy to be approved in USA. He was awarded a PhD in virology from Imperial College London prior to his move to University College London in 1991.

引用

页码：103 / 106

页数：4